The Johns Hopkins Oncology Center is dedicated to research and education in cancer and related disorders and to the prompt application of new knowledge to the treatment of patients and to the prevention of neoplastic diseases. In order to address these goals, the Medical Institutions created an Oncology Faculty and Endowment and constructed a Center facility which houses research laboratories and special clinical services. There is a broad base of ongoing cancer research at Johns Hopkins. The special scientific programs of the Oncology Center are interdisciplinary in character and are focused on human disease. A wide range of activity is encompassed ranging from fundamental research into the molecular genetics of human tumorigenesis to clinical trials of new antitumor treatments. The seven major research programs of the Center are administered by Divisions: Bone Marrow Transplantation (Santos), Cancer Biology (Baylin), Pharmacology and Experimental Therapeutics (Colvin), Radiological Science (Order), Medical Oncology (Abeloff), Pediatric Oncology (Civin), and Developmental Academic Programs (Coffey). Special educational opportunities in oncology are open to a wide variety of students at all levels of education and experience. The emphasis on the biology and treatment of human neoplasia is especially pertinent to physician-scientists. Community outreach activities include professional education and clinical research as well as patient consultation and treatment programs. Under the aegis of the State Health Department, the Center is joined with other agencies to address the cancer problems extant in the Maryland area, as well as the needs of special population groups such as minorities, the elderly, and rural residents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-31
Application #
3101234
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1978-01-01
Project End
1996-04-30
Budget Start
1993-05-01
Budget End
1994-04-30
Support Year
31
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Dean, Lorraine T; Montgomery, Madeline C; Raifman, Julia et al. (2018) The Affordability of Providing Sexually Transmitted Disease Services at a Safety-net Clinic. Am J Prev Med 54:552-558
Bastos, Diogo A; Antonarakis, Emmanuel S (2018) AR-V7 and treatment selection in advanced prostate cancer: are we there yet? Precis Cancer Med 1:
Stein-O'Brien, Genevieve; Kagohara, Luciane T; Li, Sijia et al. (2018) Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance. Genome Med 10:37
Brundage, Michael; Blackford, Amanda; Tolbert, Elliott et al. (2018) Presenting comparative study PRO results to clinicians and researchers: beyond the eye of the beholder. Qual Life Res 27:75-90
Mondul, Alison M; Joshu, Corinne E; Barber, John R et al. (2018) Longer-term Lipid-lowering Drug Use and Risk of Incident and Fatal Prostate Cancer in Black and White Men in the ARIC Study. Cancer Prev Res (Phila) 11:779-788
Lu, Dai-Yin; Yalçin, Hulya; Yalçin, Fatih et al. (2018) Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 121:1081-1089
Gordy, James T; Luo, Kun; Francica, Brian et al. (2018) Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3?-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons. J Immunother 41:181-189
Woodard, Lauren E; Dennis, Cindi L; Borchers, Julie A et al. (2018) Nanoparticle architecture preserves magnetic properties during coating to enable robust multi-modal functionality. Sci Rep 8:12706
Shrestha, Eva; White, James R; Yu, Shu-Han et al. (2018) Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol 199:161-171
Christenson, Eric S; Antonarakis, Emmanuel S (2018) PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs 23:123-133

Showing the most recent 10 out of 2393 publications